ACQUISITIONS (Details) $ in Thousands						3 Months Ended			12 Months Ended
	Nov. 17, 2015 USD ($) patent	Apr. 02, 2015 USD ($)	Dec. 17, 2013 USD ($)	Jul. 29, 2013 USD ($)	Jun. 21, 2012 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($)	Apr. 30, 2016 USD ($)
Purchase price consideration
Research and development expenses						$ 5,084	$ 5,949
Amortization expense						25,735	27,037
Pro forma financial information (unaudited)
Net revenues						90,447	104,780
Endo
ACQUISITIONS
Number of patents infringed | patent	3
Senior Notes
Purchase price consideration
Aggregate principal amount of notes issued		$ 575,000				475,000				$ 375,000
Proceeds from the issuance of debt		562,000
Cebranopadol
Purchase price consideration
Cash Paid	$ 25,000
Research and development expenses	54,900
Cebranopadol | Endo
Purchase price consideration
Amount of one-time accounting adjustment	$ 29,900
NUCYNTA
Purchase price consideration
Cash Paid		1,050,000
Rebates payable by seller		(9,977)
Total Purchase Consideration		1,040,023
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Intangible asset - acquired entity product rights		1,019,978
Inventories		11,590
Manufacturing Equipment		8,455
Estimated fair value of the assets acquired		$ 1,040,023
Estimated useful life of intangible asset		10 years
NUCYNTA | Senior Notes
Purchase price consideration
Proceeds from the issuance of debt		$ 550,000
CAMBIA
Purchase price consideration
Cash Paid			$ 48,700
Contingent consideration payable			10,000
Fair Value of contingent consideration						800			$ 1,600
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Estimated fair value of the assets acquired			49,700
CAMBIA | Contingent Consideration Liability
Purchase price consideration
Fair Value of contingent consideration			$ 1,000
Lazanda
Purchase price consideration
Cash Paid				$ 4,000
Contingent consideration payable				15,000
Fair Value of contingent consideration						7,100			11,700
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Estimated fair value of the assets acquired				12,000
Lazanda | Contingent Consideration Liability
Purchase price consideration
Fair Value of contingent consideration				$ 8,000
Zipsor
Purchase price consideration
Cash Paid					$ 26,400
Contingent consideration payable					5,000
Fair Value of contingent consideration						$ 800			$ 1,500
Amortization expense							$ 600	$ 1,000
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Estimated fair value of the assets acquired					27,700
Zipsor | Intangible Assets
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Fair Value of intangible assets					27,200
Zipsor | Contingent Consideration Liability
Purchase price consideration
Fair Value of contingent consideration					$ 1,300